📊 MD Key Takeaways
Is MD a Good Investment? Thesis Analysis
Pediatrix demonstrates solid operational performance with strong margins (10.9% operating, 8.6% net) and excellent cash generation (14.2% FCF margin), supported by healthy balance sheet metrics. However, revenue decline of 4.9% YoY and flat net income growth raise concerns about underlying business momentum, warranting cautious positioning despite improved EPS from share reduction.
Why Buy MD? Key Strengths
- Strong operating cash flow generation of $271.1M with excellent 14.2% FCF margin demonstrates high-quality earnings
- Healthy balance sheet with manageable leverage (0.69x debt/equity) and solid liquidity (1.66x current ratio)
- Exceptional return metrics (19.1% ROE, 7.4% ROA) indicate efficient capital deployment and operational effectiveness
- Robust interest coverage ratio of 10x provides substantial debt service cushion
MD Investment Risks to Consider
- Revenue contraction of 4.9% YoY signals potential market share loss or sector headwinds in healthcare services
- Flat net income growth despite improved EPS suggests earnings expansion is driven by share buybacks rather than organic growth
- Modest insider activity (only 2 Form 4 filings in 90 days) provides limited signal on management conviction
- Exposure to healthcare reimbursement pressures and regulatory risks inherent to hospital services sector
Key Metrics to Watch
- Revenue trend reversal and year-over-year growth rate acceleration
- Operating margin sustainability amid potential pricing and cost pressures
- Free cash flow conversion rate and capital allocation decisions
- Debt reduction progress and leverage trajectory relative to industry peers
MD Financial Metrics
💡 AI Analyst Insight
Pediatrix Medical Group, Inc. presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.
MD Profitability Ratios
MD vs Healthcare Sector
How Pediatrix Medical Group, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is MD Overvalued or Undervalued?
Based on fundamental analysis, Pediatrix Medical Group, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
MD Balance Sheet & Liquidity
MD 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: Pediatrix Medical Group, Inc.'s revenue has shown modest growth of 5% over the 5-year period. The most recent EPS of $-0.73 indicates the company is currently unprofitable.
MD Growth Metrics (YoY)
MD Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $492.9M | $4.0M | $0.23 |
| Q2 2025 | $468.8M | $4.0M | $0.46 |
| Q1 2025 | $458.4M | $4.0M | $0.05 |
| Q3 2024 | $506.6M | $4.0M | $0.23 |
| Q2 2024 | $500.6M | $4.0M | $0.34 |
| Q1 2024 | $491.0M | $4.0M | $0.05 |
| Q3 2023 | $489.9M | $14.2M | $0.26 |
| Q2 2023 | $486.0M | $5.9M | $0.07 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
MD Capital Allocation
MD SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for Pediatrix Medical Group, Inc. (CIK: 0000893949)
📋 Recent SEC Filings
❓ Frequently Asked Questions about MD
What is the AI rating for MD?
Pediatrix Medical Group, Inc. (MD) has an AI rating of HOLD with 62% confidence, based on fundamental analysis of SEC EDGAR filings.
What are MD's key strengths?
Claude: Strong operating cash flow generation of $271.1M with excellent 14.2% FCF margin demonstrates high-quality earnings. Healthy balance sheet with manageable leverage (0.69x debt/equity) and solid liquidity (1.66x current ratio).
What are the risks of investing in MD?
Claude: Revenue contraction of 4.9% YoY signals potential market share loss or sector headwinds in healthcare services. Flat net income growth despite improved EPS suggests earnings expansion is driven by share buybacks rather than organic growth.
What is MD's revenue and growth?
Pediatrix Medical Group, Inc. reported revenue of $1.9B.
Does MD pay dividends?
Pediatrix Medical Group, Inc. does not currently pay dividends.
Where can I find MD SEC filings?
Official SEC filings for Pediatrix Medical Group, Inc. (CIK: 0000893949) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is MD's EPS?
Pediatrix Medical Group, Inc. has a diluted EPS of $1.94.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is MD a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Pediatrix Medical Group, Inc. has a HOLD rating with 62% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is MD stock overvalued or undervalued?
Valuation metrics for MD: ROE of 19.1% (sector avg: 15%), net margin of 8.6% (sector avg: 12%). Higher ROE suggests strong returns relative to peers.
Should I buy MD stock in 2026?
Our dual AI analysis gives Pediatrix Medical Group, Inc. a combined HOLD rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is MD's free cash flow?
Pediatrix Medical Group, Inc.'s operating cash flow is $271.1M, with capital expenditures of N/A. FCF margin is 14.2%.
How does MD compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 8.6% (avg: 12%), ROE 19.1% (avg: 15%), current ratio 1.66 (avg: 2).